Inovio’s MERS vaccine yields positive results in Phase 1 study
Inovio Pharmaceuticals announced positive phase 1 results of its collaborative vaccine study with INO-4700 (GLS-5300) against the Middle East respiratory syndrome, or MERS.
Results for INO-4700, which is being co-developed by Inovio and GeneOne Life Science showed that the drug was well-tolerated and demonstrated overall high levels of antibody responses in roughly 95% of subjects, while also generating broad-based T cell responses in nearly 90% of study participants.
The phase 1, open-label, dose-escalation MERS vaccine trial, in partnership with the Walter Reed Army Institute of Research in Maryland, displayed antibody responses by ELISA in 94% of subjects at week 14 — two weeks post-third dose. Additionally, there were no statistically significant dose-dependent differences in antibody response rates — 91%, 95%, and 95% at doses of 0.67, 2, and 6 mg, respectively. Durable antibody responses to INO-4700 were also maintained through 60 weeks following dosing.
“Inovio is utilizing our versatile immunotherapy and vaccine platform to target and develop the most advanced preventive vaccine for MERS, a virulent viral infection with no medical countermeasure. This trial further demonstrates Inovio’s commitment to fighting emerging viral threats, while also continuing to validate consistent high levels of both immune and antibody responses across our infectious disease platform. We look forward to continuing this development in a partnership with GeneOne and CEPI for developing novel therapies for MERS,” Inovio president and CEO Dr. J. Joseph Kim said.
Results for INO-4700, which is being co-developed by Inovio and GeneOne Life Science showed that the drug was well-tolerated and demonstrated overall high levels of antibody responses in roughly 95% of subjects, while also generating broad-based T cell responses in nearly 90% of study participants.
The phase 1, open-label, dose-escalation MERS vaccine trial, in partnership with the Walter Reed Army Institute of Research in Maryland, displayed antibody responses by ELISA in 94% of subjects at week 14 — two weeks post-third dose. Additionally, there were no statistically significant dose-dependent differences in antibody response rates — 91%, 95%, and 95% at doses of 0.67, 2, and 6 mg, respectively. Durable antibody responses to INO-4700 were also maintained through 60 weeks following dosing.
“Inovio is utilizing our versatile immunotherapy and vaccine platform to target and develop the most advanced preventive vaccine for MERS, a virulent viral infection with no medical countermeasure. This trial further demonstrates Inovio’s commitment to fighting emerging viral threats, while also continuing to validate consistent high levels of both immune and antibody responses across our infectious disease platform. We look forward to continuing this development in a partnership with GeneOne and CEPI for developing novel therapies for MERS,” Inovio president and CEO Dr. J. Joseph Kim said.